The drug has been launched in 30mg, 100mg and 300mg latex-free, multi-dose vials.
Paclitaxel can be used alone or with other drugs as a treatment for breast cancer, ovarian cancer, non-small cell lung cancer and AIDS-related Kaposi’s sarcoma.
Sagent CEO, founder, and chairman of the board Jeffrey Yordon said the launch of paclitaxel expands their growing portfolio of injectable oncolytics to six products.